SPRAVATO® helped Nicole’s treatment-resistant depression. Now, she’s sharing her story.
SPRAVATO®
Now at Three Strand Wellness
If you’ve taken two or more oral antidepressants and still experience symptoms of depression, you might have treatment-resistant depression (TRD).
​
It might be time to talk with us about a different treatment approach. See what makes SPRAVATO® different and learn more about other patients’ experiences with SPRAVATO®.
Adults with treatment-resistant depression who were part of a clinical study were given either a nasal esketamine spray or a placebo spray. Those who added esketamine, the active ingredient in SPRAVATO®, to their oral antidepressant experienced a greater reduction of depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant. (*Based on an overall score on a standardized rating scale.)
